The Delaware Court of Chancery appears positioned to once again decide whether to keep afloat a once-promising multibillion-dollar merger that has since struck the rocks in a pair of dueling breach of contract lawsuits.
Since Abbott Laboratories agreed in January to buy Alere for $5.8 billion, the Massachusetts-based medical testing company has delayed its annual financial reporting and disclosed that it is facing three investigations by the U.S. Department of Justice into its Medicaid billing, the integrity of a product line and its overseas sales practices.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
